Reminder to exercise Initiator Pharma A/S series TO 1 warrants

The subscription period for the series TO 1 warrants issued as part of Initiator Pharma A/S’s ("Initiator Pharma") rights issue conducted during the spring of 2018 will continue until November 1, 2018. The last day for trading with the series TO 1 warrants is October 30, 2018. Holders of the series TO 1 warrants are entitled to subscribe for one new share for each warrant at a price of SEK 2.20 per share. If all of the series TO 1 warrants are exercised, 5,789,294 new shares are emitted, and Initiator Pharma is allocated approximately SEK 12.7 million before issue costs.

The subscription of shares based on series TO 1 warrants may take place until November 1, 2018 and payment needs to be cleared, on said day no later than 3:00 pm. Conversion of interim shares to shares is expected to take place during week 46.

Please note that the last day of trading of series TO 1 warrants on Spotlight Stock Market is October 30, 2018. The series TO 1 warrants will expire and lose all value, if the holder does not actively subscribe for shares by November 1, 2018 or sells their warrants by October 30, 2018.

The teaser and subscription form are available on the following websites: Initiator Pharma (www.initiatorpharma.com); Sedermera Fondkommission (www.sedermera.se) and Spotlight Stock Market (www.spotlightstockmarket.com).

Financial advisor 

Sedermera Fondkommission is the financial advisor and issuing agent to Initiator Pharma in connection with the exercise of warrants of series TO 1.

For further information about the warrants of series TO 1, please contact:

Sedermera Fondkommission

Telephone: +46 40-615 14 10

E-mail: info@sedermera.se

For further information about Initiator Pharma, please contact: 

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 

E-mail: ceo@initiatorpharma.com 

About Initiator Pharma

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for patients suffering from Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond to the current market PDE5i medications.Learn more at www.initiatorpharma.com.

About erectile dysfunction

Erectile dysfunction is characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of life style diseases such as diabetes. The large diabetic ED patient segment is often responding poorly to the current medication and is therefore of particular interest for Initiator Pharma. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, relationship problems etc. (Althof, 2002; Shabsigh et al., 1998, Tsai, 2008; Litwin et al., 1998).

This is an English translation of a press release originally drafted in Swedish. In the case of any discrepancies, the Swedish version shall prevail.